A novel embolic model of cerebral infarction and evaluation of stachybotrys microspora triprenyl phenol-7 (SMTP-7), a novel fungal triprenyl phenol metabolite

Journal of Pharmacological Sciences

Volumn 114, Issue 1, 2010, Pages 41-49

  Hashimoto, Terumasa ^a   Shibata, Keita ^a   Nobe, Koji ^a   Hasumi, Keiji ^b   Honda, Kazuo ^a  

^a SHOWA UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Acetic acid; Cerebral infarction; Embolus; Stachybotrys microspora triprenyl phenol 7 (SMTP 7)

Indexed keywords

ACETIC ACID; ALTEPLASE; ARGATROBAN; NORPHENAZONE; PHENOL DERIVATIVE; STACHYBOTRYS MICROSPORA TRIPRENYL PHENOL 7; TICLOPIDINE; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN EMBOLISM; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN TISSUE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; GERBIL; LASER DOPPLER FLOWMETRY; MALE; MIDDLE CEREBRAL ARTERY; NEUROLOGIC EXAMINATION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; STACHYBOTRYS; STACHYBOTRYS MICROSPORA;

EID: 77957967613     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.10131FP     Document Type: Article

References (33)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-1757.
2. Brown WR, Moody DM, Chakka VR, Stump DA, Hammon JW. Longer duration of cardiopulmonary bypass is associated with greater numbers of cerebral microemboli. Stroke. 2000;31:707-713.
3. Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgensten LB, Lu M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med. 1999;340:1781-1787.
4. Del Zoppo GJ. Investigational use of tPA in acute stroke. Ann Emerg Med. 1998;17:1196-1201.
5. Koizumi J, Yoshida Y, Nakasawa T, Ooneda G. Experimental studies of ischemic brain edema, I: a new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke. 1986;8:1-8.
6. Tamura A, Graham DI, McCulloch J, Teasdale GM. Focal cerebral ischemia in rat: 1. Description of technique and early neuropathological conscequences following middle cerebral artery occlusion. J Cereb Blood Flow Metab. 1981;1:53-60.
7. Sekiguchi M, Sugiyama Y, Takagi K, Takagi N, Takeo S, Tanaka O, et al. Rapid appearance of pathological changes of neurons and glia cells in the cerebellum of microsphere-embolized rats. Brain Res. 2003;978:228-232.
8. Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Asai Y, Muranaka Y, et al. A simple and reproducible cerebral thrombosis model in rats induced by a photochemical reaction and the effect of a plasminogen-plasnogen activator chimera in this model. J Pharmacol Toxicol Methods. 1993;29:165-173.
9. Kudo M, Aoyama A, Ichimori S. An animal model of cerebral infarction. Homologous blood clot emboli in rats. Stroke. 1982;13:505-508.
10. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83-92.
11. Ikoma H, Ohtsu K, Tamao Y, Kikumoto R, Mori E, Funahara Y, et al. Effect of a potent thrombin inhibitor, NO. 407, on novel experimental thrombosis generated by acetic acid. Kobe J Med Sci. 1980;26:33-45.
12. Hinata K, Hashimoto T, Ohata H, Kazuo H. The establishment of novel embolic ingarct model and assessment of tissue plasminogen activator. J Pharmacol Sci. 2008;106 Suppl:239P.
13. Shibata K, Hashimoto T, Ohata H, Honda K. The establishiment of acetic acid-induced cerebral infarct model, and evaluation of tissue plasminogen activator (t-PA), edaravone and argatroban. J Pharmocol Sci. 2009;109 Suppl:85P.
14. Shinohara C, Hasumi K, Hatsumi W, Endo A. Staplabin, a novel fungal triprenyl phenol which stimulates the binding of plasminogen to fibrin and U937 cells. J Antibiot. 1996;49:961-966.
15. Takayasu R, Hasumi K, Shinohara C, Endo A. Enhancement of fibrin binding and activation of plasminogen by staplabin through induction of conformational change in plasminogen. FEBS Lett. 1997;418:58-62.
16. Kohyama T, Hasumi K, Hamanaka A, Endo A. SMTP-1 and -2, novel analogs of staplabin produced by Stachybotrys microspore IFO30018. J Antibiot. 1997;50:172-174.
17. Hasumi K, Ohyama S, Kohyama T, Ohsaki Y, Takayasu R, Endo A. Isolation of SMTP-3, 4, 5 and -6, novel analogs of staplabin, and their effects on plasminogen activation and fibrinolysis. J Antibiot. 1998;51:1059-1068.
18. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rat. Stroke. 1989;20:84-91.
19. Yoshimine T, Hayakawa T, Yamada K, Takemoto O, Kato A, Ushio Y, et al. Regional cerebral ischemia in the gerbil: Measurement of regional CBF by quantitative autoraduography. J Cereb Blood Flow Metab. 1986;6:348-357.
20. Ginsberg MD, Busto R. Rodent models of cerebral ischemia. Stroke. 1989;20:1627-1642.
21. Overgaard K, Sereghy T, Boysen G, Pedersen H, Heyer S, Diemer NH. A rat model of reproducible cerebral infarction using thrombotic blood clot emboli. J Cereb Blood Flow Metab. 1992;12:484-490.
22. Zhang WP, Wei EQ, Mei RH, Zhu CY, Zhao MH. Neuroprotective effect of ONO-1087, a leukotriene receptor antagonist, on focal cerebral ischemia in rats. Acta Pharmacol Sin. 2002;23:871-877.
23. Sakurama T, Kitamura R, Kaneko M. Tissue-type plasminogen activator improves neurogical functions in rat model of thromboembolic stroke. Stroke. 1994;25:451-456.
24. Takatsuru Y, Fukumoto D, Yoshitomo M, Nemoto T, Tsukada H, Nabekura J. Neuronal circuit remodeling in the contralateral cortical hemisphere during functional recovery from cerebral infarction. J Neurosci. 2009;29:10081-10086.
25. Okubo S, Igarashi H, Kanamatsu T, Hasegawa D, Orima H, Katayama Y. FK-506 extended the therapeutic time window for thrombolysis without the risk of hemorrhagic transformation in embolic rat stroke model. Brain Res. 2007;1143:221-227.
26. Orset C, Macrez R, Young AR, Panthou D, Angles-Cano E, Maubert E, et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke. 2007;38:2771-2778.
27. The National Institute of Neurogical Disorder and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
28. Niessen F, Hilger T, Hoehn M, Hossmann KA. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke. 2003;34:2019-2024.
29. Watanabe T, Yuki S, Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268:1597-1604.
30. Zhang W, Sato K, Hayashi T, Omori N, Nagano I, Kato S, et al. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain. Neurol Res. 2004;26:342-348.
31. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008;39:3372-3377.
32. Wang Q, Tang XN, Yenari MA. The inflammatory response in stroke. J Neuroimmunol. 2007;184:53-68.
33. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758.